WHO Drug Information Vol. 16, No. 2, 2002
(2002; 91 pages) Ver el documento en el formato PDF
Índice de contenido
Abrir esta carpeta y ver su contenidoHerbal Medicines
Abrir esta carpeta y ver su contenidoCurrent Topics
Abrir esta carpeta y ver su contenidoGood Clinical Practices
Abrir esta carpeta y ver su contenidoSafety Information
Cerrar esta carpetaRegulatory Action
Ver el documentoAlosetron hydrochloride: restricted marketing
Ver el documentoBaclofen: abrupt discontinuation dangerous
Ver el documentoIrinotecan: prescribing changes
Ver el documentoSodium oxybate/GHB approved for cataplexy
Ver el documentoRofecoxib: new indication and label changes
Abrir esta carpeta y ver su contenidoEssential Medicines
Abrir esta carpeta y ver su contenidoRecent Publications and Sources of Information
Ver el documentoProposed International Nonproprietary Names: List 87

Irinotecan: prescribing changes

United States of America - Changes in the prescribing information for irinotecan (Campto-sar®), indicated as a component of therapy for first-line treatment of metastatic colorectal cancer in combination with 5-fluorouracil (5-FU) and leucov-orin (LV) and for treatment of metastatic colorectal cancer that has recurred or progressed following initial 5-FU based treatment.

The following labelling changes arose following recommendations made at a meeting of the Food and Drug Administration’s Oncologic Drugs Advisory Committee.

• Both the bolus and the infusional regimens of CAMPTOSAR plus 5-FU/LV® remain approved for the first-line treatment of patients with meta-static colorectal cancer.

• The starting dose and schedule for both regimens remain unchanged.

The prescribing information has been revised to identify patients at higher risk of severe toxicity, to clarify dose modification guidelines, and to augment the information about management of treatment-related toxicities.

Reference: Pharmacia Oncology Web site http://www.pharmaciaoncology.com

Ir a la sección anterior
Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 29 octubre 2018